Jane Robertson, BSc, MBCHB, MD
AstraZeneca
12
0
9
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (12)
Showing 10 of 12 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Bella Kaufman, MD
Chaim Sheba Medical Centre, Tel Hashomer, Israel
Shared therapeutic areas:
Worked with same sponsors:
Prof Jan HM Schellens
The Netherlands Cancer Institute, Amsterdam, The Netherlands
Shared therapeutic areas:
Worked with same sponsors:
Dr Johann de Bono, MD
Cancer Research UK, The Institute of Cancer Research, London, UK
Shared therapeutic areas:
Worked with same sponsors:
Dr. Johann De Bono, PhD MRCP FRCR
Royal Marsden Hospital Trust, London, UK
Shared therapeutic areas:
Worked with same sponsors:
Karen Gelmon, MD
British Columbia Cancer Agency
Shared therapeutic areas:
Worked with same sponsors:
Stan Kaye, Professor
Royal Marsden NHS Foundation Trust
Shared therapeutic areas:
Worked with same sponsors:
Yung-Jue Bang, MD
Seoul National University Hospital
Shared therapeutic areas:
Worked with same sponsors:
Amit Oza, MD
Princess Margaret Hospital, Canada
Shared therapeutic areas:
Worked with same sponsors:
Bert H O'Neil, MD
Aptium Oncology Gastrointestinal Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Judy E Garber
Dana-Farber Cancer Institute
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (12)
Showing 12 of 12 trials
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
Phase I AZD2281/Cisplatin in Advanced Solid Tumour Patients
Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer
Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status
All 12 trials loaded